Abigail Brooks, MA

Mathew emphasizes the importance of routine liver cancer screening in patients with advanced liver disease and the need to overcome insurance barriers for HCC panel testing.

Iordache emphasizes the importance of a multidisciplinary approach to liver disease care in pregnant patients and the need for patient education.

Legaspi reviews different treatment options for managing ascites, ranging from limiting dietary sodium intake to diuretic use and therapeutic paracentesis.

Franco describes the importance of discussing pregnancy intentions with patients with liver disease and the need for multidisciplinary comanagement of these patients.

Mathew reviews common reasons for diagnostic delays in PBC, emphasizing the importance of timely identification and prompt treatment for improving patient outcomes.

Janovsky explains the importance of nutrition and dietary interventions in MASH and cirrhosis management, reviewing how providers can discuss both with patients.

Richards describes the utility of different NITs in primary and specialty care for risk-stratifying patients with MASH and fibrosis.

Solomon explains how to navigate the growing Crohn disease treatment armamentarium and the importance of treatment positioning.

Iordache reviews complications of diagnosing hepatobiliary disease in pregnancy and explains how these patients typically present.

Martinez de Andino reviews key considerations for the management of DGBI with brain-gut behavioral therapy and neuromodulators.

The decision is based on rates of clinical and endoscopic remission with guselkumab in the ongoing phase 2b/3 QUASAR study.

Low birth weight and being small for gestational age were linked to a greater risk of developing pediatric-onset MASLD and progressive liver disease.

Findings highlight disease burden and ongoing unmet needs in patients with IBS-C and IBS-D, suggesting the benefit of prescription medications on rates of satisfaction and symptom control.

Findings underscore the importance of alcohol cessation in patients with steatotic liver disease, suggesting a synergistic effect between steatosis and alcohol on disease progression.

There was no difference in the incidence of BKPyV, CMV, or EBV in patients who received HCV NAT-positive donor kidneys versus those who received HCV NAT-negative donor kidneys.

Patients with positive endoscopic findings for upper gastrointestinal mucosal damage had a greater risk of developing Parkinson disease compared to those without mucosal damage.

People with chronic liver disease were more likely to experience healthcare barriers and require recurrent acute care compared to those with COPD and/or CVD.

Barratt reflects on recent therapeutic developments in IgAN, the most recent being the full FDA approval of sparsentan (Filspari), and the importance of preventing kidney failure.

Findings support the use of FIB-4’s low cut-off for ruling out severe fibrosis and cirrhosis as well as the use of Forns index’s high cut-off for significant fibrosis in chronic HCV.

The FDA has granted full approval to sparsentan (Filspari) for slowing kidney function decline in adults with IgAN at risk of disease progression based on PROTECT trial data.

The Delphi survey collected opinions from members of the European Alpha-1 Research Collaboration to guide the diagnosis, treatment, and management of severe AATD.

The August 2024 month in review highlights our coverage of pipeline news, a cross-specialty feature about dialysis, and other recent renal news and research from the past few weeks.

This August 2024 month in review spotlights HCPLive’s top coverage of hepatic pipeline news and recent research in liver disease, HCV, and more.

Rizk discusses the recent FDA accelerated approval of iptacopan (Fabhalta) and reflects on the significance of other therapeutic developments in IgAN.

The decision to revoke the conditional marketing authorization is based on a June 2024 CHMP recommendation from the EMA suggesting the benefits of Ocaliva do not outweigh its risks.

The HCPLive August gastroenterology month in review spotlights expansions in gastrointestinal treatment and screening access as well as the newest edition of Qazi Corner.

Data for more than 2 million blood donors in Canada provides insight into HCV antibody positivity trends in this notoriously low-risk patient population.

Findings from a recent national registry study suggest perioperative mortality after living kidney donation significantly declined in 2013-2022 compared with 1993-2002 and 2003-2012.

The restrictive strategy led to fewer cholecystectomies without increasing complications but did not improve pain-free outcomes versus usual care for symptomatic cholelithiasis.

The majority of highly suspected COVID-19 vaccine-associated glomerular disease cases were diagnosed as immunoglobulin A nephropathy and eventually improved with treatment.